Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy

Stroke is a leading cause of long-term disability worldwide, often resulting in spasticity. Botulinum toxin injections have emerged as a cornerstone in the management of post-stroke spasticity. However, despite their clinical efficacy, maintaining long-term adherence to botulinum toxin therapy remains a significant challenge. This retrospective observational study analyzed 106 patients undergoing botulinum toxin therapy for post-stroke spasticity to identify the key factors influencing treatment continuation. The mean age of the cohort at the time of stroke was 57.7 years, with ischemic strokes accounting for 61.3% of cases and hemorrhagic strokes for 38.7%. A total of 61.3% of patients continued therapy, while 38.7% discontinued therapy due to a variety of reasons. The most common reasons included logistical barriers (43.9%) and comorbidities (36.6%), followed by perceived lack of benefit (24.4%) and clinical resolution (12.2%). Among those citing a lack of benefit, muscular fibrosis was a notable contributor. In the multivariable Cox regression analysis, logistical challenges, such as access to healthcare facilities and administrative difficulties, were associated with discontinuation (HR = 13.95, 95% CI: 5.57-34.94, <i>p</i> < 0.001). Comorbidities also significantly increased the likelihood of discontinuation (HR = 3.51, 95% CI: 1.56-7.87, <i>p</i> = 0.002), as did the lack of benefit (HR = 14.34, 95% CI: 5.65-36.38, <i>p</i> < 0.001) and condition resolution (HR = 19.20, 95% CI: 5.58-66.02, <i>p</i> < 0.001). In contrast, demographic and clinical factors, including age at the time of stroke, gender, stroke type, affected side, and baseline spasticity severity, did not significantly influence treatment continuation. These findings underscore the importance of addressing logistical barriers and mitigating the burden of comorbidities to enhance treatment adherence. A shift toward patient-centered approaches that integrate robust rehabilitation services and streamline healthcare accessibility is critical for optimizing outcomes.

Authors

Institutions

Publication Details

Journal
Toxins
Published
2025-02-22
DOI
https://doi.org/10.3390/toxins17030102
Citations
3
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
4.17
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy

Laura Mori, Luca Puce, Filippo Cotellessa, Carlo Trompetto et al.
3 citations
Toxins
Botulinum Toxin and Related Neurological Disorders
4.17
article

Barriers to Long-Term Adherence in Botulinum Toxin Therapy for Post-Stroke Spasticity: Insights and Implications from a Single-Center Study in North Italy

Laura Mori, Luca Puce, Filippo Cotellessa, Carlo Trompetto, Ester Cecchella, Nicola Luigi Bragazzi, William Campanella, Lucio Marinelli, Cristina Schenone, Antonio Currà
article en
3 citations

Abstract

Stroke is a leading cause of long-term disability worldwide, often resulting in spasticity. Botulinum toxin injections have emerged as a cornerstone in the management of post-stroke spasticity. However, despite their clinical efficacy, maintaining long-term adherence to botulinum toxin therapy remains a significant challenge. This retrospective observational study analyzed 106 patients undergoing botulinum toxin therapy for post-stroke spasticity to identify the key factors influencing treatment continuation. The mean age of the cohort at the time of stroke was 57.7 years, with ischemic strokes accounting for 61.3% of cases and hemorrhagic strokes for 38.7%. A total of 61.3% of patients continued therapy, while 38.7% discontinued therapy due to a variety of reasons. The most common reasons included logistical barriers (43.9%) and comorbidities (36.6%), followed by perceived lack of benefit (24.4%) and clinical resolution (12.2%). Among those citing a lack of benefit, muscular fibrosis was a notable contributor. In the multivariable Cox regression analysis, logistical challenges, such as access to healthcare facilities and administrative difficulties, were associated with discontinuation (HR = 13.95, 95% CI: 5.57-34.94, <i>p</i> < 0.001). Comorbidities also significantly increased the likelihood of discontinuation (HR = 3.51, 95% CI: 1.56-7.87, <i>p</i> = 0.002), as did the lack of benefit (HR = 14.34, 95% CI: 5.65-36.38, <i>p</i> < 0.001) and condition resolution (HR = 19.20, 95% CI: 5.58-66.02, <i>p</i> < 0.001). In contrast, demographic and clinical factors, including age at the time of stroke, gender, stroke type, affected side, and baseline spasticity severity, did not significantly influence treatment continuation. These findings underscore the importance of addressing logistical barriers and mitigating the burden of comorbidities to enhance treatment adherence. A shift toward patient-centered approaches that integrate robust rehabilitation services and streamline healthcare accessibility is critical for optimizing outcomes.

ToxinsVol. 17(3)
Ospedale Policlinico San Martino (IT), University of Genoa (IT), Sapienza University of Rome (IT)
Good health and well-being
Openalex Percentile: Top 7%
Botulinum Toxin and Related Neurological Disorders
4.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.